No Data
No Data
Zhi Xiang Jintai (688443.SH): GR1802 injection starts phase III clinical trial for chronic sinusitis with nasal polyps indication.
On August 6th, Gelonghui reported that Zhixiang Jintai (688443.SH) announced the launch of a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial to evaluate the effectiveness, safety and immunogenicity of GR1802 injection in patients with chronic sinusitis and nasal polyps. The company completed a meeting with the Center for Drug Evaluation (CDE) EOP2 (phase II clinical trial completion/phase III clinical trial initiation) of the State Administration for Drug Supervision and Administration for drug evaluation, and it will officially launch the phase III clinical trial. GR1802 injection is a recombinant human anti-IL- drug independently developed by the company.
Institutions Along With Private Equity Firms Who Hold Considerable Shares InChongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Come Under Pressure; Lose 5.6% of Holdings Value
Zhixiang Jintai (688443.SH): the preventive tetanus drug "GR2001 injection" has been included in the list of breakthrough therapies.
Zhixiang Jintai (688443.SH) announced that the company's pharmaceutical, GR2001 injection, has been approved by the National Medical Products Administration of China.
Zhixiang Jintai (688443.SH): At the end of the term, Jiang Ren, the actual controller, increased the company's shares by about 31.22,200 yuan
Gelonghui, May 17, 丨 Zhixiang Jintai (688443.SH) announced that as of May 16, 2024, the actual controller, Mr. Jiang Rensheng, had increased his holdings of the company's 875,582 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for about 0.24% of the company's total issued share capital. The total increase amount amount of about RMB 31.22,200 million has been reached, reaching the lower limit of the increase range of RMB 30 million. The period of this increase plan has expired and the implementation of the increase in holdings has been completed.
Is Chongqing Genrix Biopharmaceutical (SHSE:688443) Using Too Much Debt?
Zhixiang Jintai (688443.SH) reported first-quarter results with a net loss of 164 million yuan
Zhixiang Jintai (688443.SH) released its report for the first quarter of 2024, with revenue of 6,330.27...
No Data